Clinical trial · Interventional
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
NCT00912899CI-TRIAL-00024185terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated early due to lack of clinical response.
Summary
Brief summary (as posted)
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Noscapine HCl | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- One
- description
- Noscapine HCl
- interventionNames
- Drug: Noscapine HCl
Primary outcomes (1)
- measure
- To determine the maximum tolerated dose
- timeFrame
- During the first 28 day treatment cycle
Secondary outcomes (3)
- measure
- To determine the safety and tolerability in the study population
- timeFrame
- End of the study treatment
- measure
- To evaluate the pharmacokinetics of study drug
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced Multiple Myeloma. * Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®). * ECOG performance status of either 0 or 1. Exclusion Criteria: * Prior chemotherapy with antimicrotubule agents * Metastasis involving the brain or spinal cord * Clinically significant lung or heart disease * Abnormal electrocardiogram Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria. Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.
References
Publications (0)
Data not yet available
No reference posted for this study.